FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2155744329> ?p ?o ?g. }

• W2155744329 endingPage "7406" @default.
• W2155744329 startingPage "7401" @default.
• W2155744329 abstract "Abstract Purpose: To characterize the pharmacokinetics of temsirolimus and its major metabolite, sirolimus, in patients receiving enzyme-inducing antiepileptic drugs (EIAED) compared with patients receiving non-EIAEDs. An additional objective was to determine whether concentrations of temsirolimus or sirolimus were achieved in brain tumor tissue. Experimental Design: Patients with recurrent malignant gliomas not receiving EIAEDs initially received temsirolimus weekly at a dose of 250 mg i.v. The dose was subsequently reduced to 170 mg due to intolerable side effects. For patients taking EIAEDs, the starting dose of temsirolimus was 250 mg with standard dose escalation until the maximal tolerated dose was established. Ten whole blood samples were obtained over a period of 24 h after administration of temsirolimus for pharmacokinetic assessments. Patients eligible for cytoreductive surgery received temsirolimus before tumor resection. Whole blood and tumor tissue were obtained for analysis. Results: Significant differences in the pharmacokinetic variables for temsirolimus and sirolimus were observed between the two patient groups at a comparable dose level of 250 mg. For patients receiving EIAEDs, the systemic exposure to temsirolimus was lower by 1.5-fold. Likewise, peak concentrations and exposure to sirolimus were lower by 2-fold. Measurable concentrations of temsirolimus and sirolimus were observed in brain tumor specimens. The average tissue to whole blood ratio for temsirolimus was 1.43 and 0.84 for sirolimus. Conclusions: Drugs that induce cytochrome P450 3A4, such as EIAEDs, significantly affect the pharmacokinetics of temsirolimus and its active metabolite, sirolimus. Total exposure to temsirolimus and sirolimus was lower in the EIAED group at the maximum tolerated dose of 250 mg compared with the non-EIAED group at the maximum tolerated dose of 170 mg. However, brain tumor tissue concentrations of temsirolimus and sirolimus were relatively comparable in both groups of patients at their respective dose levels. Correlative analyses of the tissue for the inhibition of the key regulators (p70S6 kinase and 4E-binding protein 1) of mammalian target of rapamycin are necessary to define the therapeutic significance of the altered exposure to temsirolimus." @default.
• W2155744329 created "2016-06-24" @default.
• W2155744329 creator A5003825991 @default.
• W2155744329 creator A5005194857 @default.
• W2155744329 creator A5015598221 @default.
• W2155744329 creator A5021656597 @default.
• W2155744329 creator A5023905352 @default.
• W2155744329 creator A5027150108 @default.
• W2155744329 creator A5029952866 @default.
• W2155744329 creator A5040044145 @default.
• W2155744329 creator A5046264008 @default.
• W2155744329 creator A5048649057 @default.
• W2155744329 creator A5051168746 @default.
• W2155744329 creator A5061018141 @default.
• W2155744329 creator A5063511816 @default.
• W2155744329 creator A5064593201 @default.
• W2155744329 creator A5070190752 @default.
• W2155744329 creator A5075492015 @default.
• W2155744329 date "2007-12-15" @default.
• W2155744329 modified "2023-10-03" @default.
• W2155744329 title "Pharmacokinetic and Tumor Distribution Characteristics of Temsirolimus in Patients with Recurrent Malignant Glioma" @default.
• W2155744329 cites W1995197723 @default.
• W2155744329 cites W2003043566 @default.
• W2155744329 cites W2025137878 @default.
• W2155744329 cites W2042555740 @default.
• W2155744329 cites W2050080951 @default.
• W2155744329 cites W2098176107 @default.
• W2155744329 cites W2114438728 @default.
• W2155744329 cites W2139482461 @default.
• W2155744329 cites W2147394591 @default.
• W2155744329 cites W2147775209 @default.
• W2155744329 cites W2150937214 @default.
• W2155744329 cites W2156729202 @default.
• W2155744329 cites W4244279664 @default.
• W2155744329 doi "https://doi.org/10.1158/1078-0432.ccr-07-0781" @default.
• W2155744329 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4918812" @default.
• W2155744329 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18094423" @default.
• W2155744329 hasPublicationYear "2007" @default.
• W2155744329 type Work @default.
• W2155744329 sameAs 2155744329 @default.
• W2155744329 citedByCount "72" @default.
• W2155744329 countsByYear W21557443292012 @default.
• W2155744329 countsByYear W21557443292013 @default.
• W2155744329 countsByYear W21557443292014 @default.
• W2155744329 countsByYear W21557443292015 @default.
• W2155744329 countsByYear W21557443292016 @default.
• W2155744329 countsByYear W21557443292017 @default.
• W2155744329 countsByYear W21557443292018 @default.
• W2155744329 countsByYear W21557443292019 @default.
• W2155744329 countsByYear W21557443292020 @default.
• W2155744329 countsByYear W21557443292021 @default.
• W2155744329 countsByYear W21557443292022 @default.
• W2155744329 countsByYear W21557443292023 @default.
• W2155744329 crossrefType "journal-article" @default.
• W2155744329 hasAuthorship W2155744329A5003825991 @default.
• W2155744329 hasAuthorship W2155744329A5005194857 @default.
• W2155744329 hasAuthorship W2155744329A5015598221 @default.
• W2155744329 hasAuthorship W2155744329A5021656597 @default.
• W2155744329 hasAuthorship W2155744329A5023905352 @default.
• W2155744329 hasAuthorship W2155744329A5027150108 @default.
• W2155744329 hasAuthorship W2155744329A5029952866 @default.
• W2155744329 hasAuthorship W2155744329A5040044145 @default.
• W2155744329 hasAuthorship W2155744329A5046264008 @default.
• W2155744329 hasAuthorship W2155744329A5048649057 @default.
• W2155744329 hasAuthorship W2155744329A5051168746 @default.
• W2155744329 hasAuthorship W2155744329A5061018141 @default.
• W2155744329 hasAuthorship W2155744329A5063511816 @default.
• W2155744329 hasAuthorship W2155744329A5064593201 @default.
• W2155744329 hasAuthorship W2155744329A5070190752 @default.
• W2155744329 hasAuthorship W2155744329A5075492015 @default.
• W2155744329 hasBestOaLocation W21557443291 @default.
• W2155744329 hasConcept C112705442 @default.
• W2155744329 hasConcept C126322002 @default.
• W2155744329 hasConcept C183713625 @default.
• W2155744329 hasConcept C185592680 @default.
• W2155744329 hasConcept C190283241 @default.
• W2155744329 hasConcept C2776820818 @default.
• W2155744329 hasConcept C2777921159 @default.
• W2155744329 hasConcept C2778227246 @default.
• W2155744329 hasConcept C502942594 @default.
• W2155744329 hasConcept C55493867 @default.
• W2155744329 hasConcept C71924100 @default.
• W2155744329 hasConcept C86554907 @default.
• W2155744329 hasConcept C98274493 @default.
• W2155744329 hasConceptScore W2155744329C112705442 @default.
• W2155744329 hasConceptScore W2155744329C126322002 @default.
• W2155744329 hasConceptScore W2155744329C183713625 @default.
• W2155744329 hasConceptScore W2155744329C185592680 @default.
• W2155744329 hasConceptScore W2155744329C190283241 @default.
• W2155744329 hasConceptScore W2155744329C2776820818 @default.
• W2155744329 hasConceptScore W2155744329C2777921159 @default.
• W2155744329 hasConceptScore W2155744329C2778227246 @default.
• W2155744329 hasConceptScore W2155744329C502942594 @default.
• W2155744329 hasConceptScore W2155744329C55493867 @default.
• W2155744329 hasConceptScore W2155744329C71924100 @default.
• W2155744329 hasConceptScore W2155744329C86554907 @default.
• W2155744329 hasConceptScore W2155744329C98274493 @default.
• W2155744329 hasIssue "24" @default.

• next